https://www.optimumcomms.com/wp-content/uploads/2023/07/SynendosTx_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-18 08:10:232023-07-18 08:10:23Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference
https://www.optimumcomms.com/wp-content/uploads/2023/07/SynendosTx_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-18 08:10:232023-07-18 08:10:23Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-17 07:09:592023-07-17 07:09:59Futura Medical Announces Agreement With Haleon To Commercialise MED3000 In The USA
https://www.optimumcomms.com/wp-content/uploads/2023/06/Vicore_Pharma_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-13 12:21:192023-07-13 12:21:19Vicore announces the appointment of Ahmed Mousa as CEO
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-11 13:08:432023-07-11 13:08:43Neuraxpharm expands outside Europe into Brazil and Mexico
https://www.optimumcomms.com/wp-content/uploads/2023/06/Versameb_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-11 08:34:492023-07-11 08:34:49Versameb Strengthens its Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2023/06/Sequana_Medical_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-10 09:23:452023-07-10 09:24:04Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
https://www.optimumcomms.com/wp-content/uploads/2023/06/Destiny_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-06 09:02:092023-07-06 09:02:09Destiny Pharma plc – Positive findings from recent SAB meeting
https://www.optimumcomms.com/wp-content/uploads/2023/06/Sequana_Medical_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-06 08:11:022023-07-06 08:11:02Sequana Medical – 1,000th alfapump® implant completed
https://www.optimumcomms.com/wp-content/uploads/2023/02/Pheon_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-05 13:05:032023-07-05 13:05:32Pheon Therapeutics enters into license agreement with Biocytogen Pharmaceuticals
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-07-05 08:55:192023-07-05 08:55:32Biocomposites invests in Renovos Biologics – developers of the RENOVITE® nanoclay therapeutic delivery platform
https://www.optimumcomms.com/wp-content/uploads/2023/06/DelSiTech_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-06-29 10:06:082023-07-04 17:18:08DelSiTech Announces Positive Topline Clinical Data From Phase 1 Trial With Its Sustained Release Eye Drop Platform
https://www.optimumcomms.com/wp-content/uploads/2023/06/Destiny_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-06-29 09:05:272023-06-29 09:05:27Destiny Pharma plc – Business Update
https://www.optimumcomms.com/wp-content/uploads/2023/06/Template_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-06-29 08:00:092023-06-29 07:16:55Vesalius Biocapital Announces First Close of Fourth Fund Raising EUR 95 Million
https://www.optimumcomms.com/wp-content/uploads/2023/06/Poolbeg_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-06-29 07:12:542023-06-29 07:12:54Poolbeg Pharma plc – Successful Artificial Intelligence led programme identifies multiple influenza drug targets
https://www.optimumcomms.com/wp-content/uploads/2023/06/MinervaX_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-06-27 10:32:452023-06-28 09:14:13MinervaX Announces Completion of Enrolment in Phase 1 Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults
https://www.optimumcomms.com/wp-content/uploads/2023/06/Template_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-06-27 07:08:312023-06-28 09:16:24Astraveus raises €16.5 Million Series Seed round to advance the development of its automated, microfluidic Cell and Gene Therapy manufacturing platformWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
